To Challenge Intellectual Property Appellate Board Verdict Rejecting Its Patent Plea For Cancer Drug
Nina Mehta MUMBAI

THE Indian subsidiary of Swiss drugmaker Novartis will challenge a decision by the Intellectual Property Appellate Board (IPAB) that said its cancer drug Glivec was not patentable.